The company insists on scientific and technological innovation as the driving force, and the technology center is rated as the national enterprise technology center. The innovative drug research and development team composed of more than 300 elites at home and abroad undertakes a number of "Twelfth Five-Year Plan" major new drug creation projects, and constantly promotes more innovative drug products to clinical applications. A number of research and development achievements of the company were awarded as "National Key New Products" and "Guangdong High-tech Products", and won the honors of "Guangdong Science and Technology Award" and "Shenzhen Science and Technology Progress Award". All products and workshops of the company have passed the domestic GMP certification, Daya Bay production base has passed the EU GMP certification, and Taijia, the key product, has obtained the EU 12 listing license, and all kinds of products enjoy a good reputation in the industry. At the same time, the company actively and continuously carried out in-depth cooperation with scientific research institutes at home and abroad, and jointly established the "Tsinghua University-Xinlitai Small Molecule Drug Joint R&D Center" with Tsinghua University, and jointly established a joint laboratory and innovative drug R&D platform with Shanghai Institute of Medical Engineering to continuously promote the development of medical science and technology.
For more than ten years, the company has been forging ahead, operating in good faith, constantly polishing product quality and persisting in fulfilling its social responsibilities. Up to now, it has returned nearly 50 million yuan to the society, and the company has also won "Top 20 Potential Enterprises of Forbes China", "Top 200 Small and Medium Listed Companies of Forbes Asia", "Top 20 Listed Companies of China Chemical Agency 10" and "Top 20 Most Competitive Listed Companies of China".
Facing the future, the company is guided by patients' needs, giving full play to its own advantages in innovative drug research and development, leading by high-end prescription drugs and biomedical devices, forming a competitive advantage by differentiation, striving to build a scientific and systematic prevention and treatment system, and contributing to human health through continuous improvement and innovation of "soft power".
Legal Representative: Ye Chenghai.
Date of establishment:1998-11-03.
Registered capital: 10460 1.6 million yuan.
Location: Guangdong Province
Unified social credit code: 9 1440300708453259J
Business status: surviving (in business, in business, on record)
Industry: manufacturing industry
Company type: joint-stock company (Sino-foreign joint venture, listed)
Personnel size: 50-99 people
Address: 37th Floor, Main Building of Lv Jing Square, Chegong Temple, No.6009 Shennan Avenue, Futian District, Shenzhen.
Scope: Import and export business of goods and technologies (excluding import distribution business); Have your own real estate lease. Development, research and production of chemical raw materials, powder injections, tablets and capsules.